Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-03-20
2008-10-07
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07432252
ABSTRACT:
The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2and/or P2Y4purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.
REFERENCES:
patent: 3639561 (1972-02-01), Gordon et al.
patent: 3639562 (1972-02-01), Gordon et al.
patent: 5292498 (1994-03-01), Boucher
patent: 5596088 (1997-01-01), Boucher et al.
patent: 5607836 (1997-03-01), Boucher et al.
patent: 5628984 (1997-05-01), Boucher
patent: 5635160 (1997-06-01), Stutts et al.
patent: 5656256 (1997-08-01), Boucher et al.
patent: 5691156 (1997-11-01), Boucher et al.
patent: 5763447 (1998-06-01), Jacobus et al.
patent: 5789391 (1998-08-01), Jacobus et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5902567 (1999-05-01), Boucher
patent: 5935555 (1999-08-01), Stutts et al.
patent: 5958897 (1999-09-01), Jacobus et al.
patent: 5962432 (1999-10-01), LaCroix et al.
patent: 5968913 (1999-10-01), LaCroix et al.
patent: 5972904 (1999-10-01), Jacobus et al.
patent: 5981506 (1999-11-01), Jacobus et al.
patent: 6022527 (2000-02-01), Boucher et al.
patent: 6133247 (2000-10-01), Boucher et al.
patent: 6143279 (2000-11-01), Boucher et al.
patent: 6159952 (2000-12-01), Shaffer et al.
patent: 0566132 (1993-10-01), None
patent: WO 94/08593 (1994-04-01), None
patent: WO 95/10538 (1995-04-01), None
patent: WO 96/40059 (1996-12-01), None
patent: WO 97/29456 (1997-08-01), None
patent: WO 97/35591 (1997-10-01), None
patent: WO 98/03177 (1998-01-01), None
patent: WO 98/03182 (1998-01-01), None
patent: WO 98/15835 (1998-04-01), None
patent: WO 98/19685 (1998-05-01), None
patent: WO 98/34593 (1998-08-01), None
patent: WO 98/34942 (1998-08-01), None
patent: WO 99/01138 (1999-01-01), None
patent: WO 99/05155 (1999-02-01), None
patent: WO 99/09998 (1999-03-01), None
patent: WO 99/32085 (1999-07-01), None
patent: WO 99/61012 (1999-12-01), None
patent: WO 00/02552 (2000-01-01), None
patent: WO 00/30629 (2000-02-01), None
patent: WO 00/36029 (2000-06-01), None
patent: WO 00/39145 (2000-07-01), None
patent: WO 00/50024 (2000-08-01), None
Gorodeski et al., American J. of Physiol., vol. 268, C1215-26, 1995.
Yerxa et al., “P2y2 Receptor Agonists: Structure, Activity and Therapeutic Utility,” Drugs of the Future, 24(7), 759-769 (1999).
(U) Yerxa et al., “P2y2 Receptor Agonists: Structure, Activity and Therapeutic Utility,” Drugs of the Future, 24(7), 759-769 (1999).
(V) Shaver et al., “Structure-Activity Relationships of Dinucleotides: Potent and Selective Agonists of P2Y Receptors,” Purinergic Signalling, 1, 183-191 (2005).
Olivier, K., et al., “Acute Safety and Effects on Mucociliary Clearance of Aerosolized Uridine 5′—Triphosphate+Amiloride in Normal Human Adults,”—Am. J. Respir. Crit. Care Med. 154:217-223 (1996).
Andersson, K., et al., “Intrauterine Release of Levonorgestrel—A New Way of Adding Progestogen in Hormone Replacement Therapy,”Obstet. Gynecol. 79(6):963-967 (1992).
Bhadauria, S. et al., “Genital tract abnormalities and female sexual function impairment in systemic sclerosis,”Am. J. Obs. Gynecol. 172:580-587 (1995).
Cust, M., et al., “Consequences and treatment of ovarian failure after total body irradiation for leukaemia,”Brit. Med. J. 299;1494-1497 (1989).
Harlap, S., :The benefits and risks of hormone replacement therapy: An epidemiologic overview,Am. J. Obstet. Gynecol., 166:1986-1992 (1992).
Key, E. et al., “Management of vaginal dryness”,Clinical Gynaecology5 (31):24-27 (1991).
Lethem, M., et al., “Nucleotide Regulation of Goblet Cells in Human Airway Epithelial Explants: Normal Exocytosis in Cystic Fibrosis,”Am. J. Respir. Cell Mol. Biol, 9:315-322 (1993).
Lichtman, R., “Perimenopausal Hormone Replacement Therapy,”J. Nurse Midwifery, 36:30-48 (1991).
Marchesoni, D., et al., “Gynaecological aspects of primary Sjorgren's syndrome,”Eur. J. Obstet. Gynecol. Reprod. Biol, 63:49-53 (1995).
Mason, S., et al., “Regulation of Transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium,”Br. J. Pharmacol., 103:1649-1656 (1991).
“Surgically Confirmed Gallbladder Disease, Venous Thromboembolism, and Breast Tumors in Relation to Postmenopausal Estrogen Therapy,”N. Eng. J. Med., 290:15-19 (1974).
Reginald, W. et al., “Medroxyprogesterone acetate in the treatment of pelvic pain due to venous congestion,”Br. Obstet. Gynecol., 96:1148-1152 (1989).
Sorokin, Y. et al., “Obstetric and Gynecologic Dysfunction in the Ehlers-Danlos Syndrome,”J. Reprod. Med., 59:281-284 (1994).
Sreebny L. et al., “Xerostomia in Diabetes Mellitus,”Diabetes Care15:900-904 (1992).
Stumpf, P., “Pharmacokinetics of Estrogen,”Obstet. Gynecol., 75(4):9S-14S (1990).
Whitehead, M., et al., “Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal Endometrium,”N. Eng. J. Med., 305(27):1599-1605 (1981).
Wisniewski, P. et al., “Postpartum vaginal atrophy,”Am. J. Obstet. Gynecol. 165:1249-1254 (1991).
Gorodeski, G.I., et al., “Regulation by retinoids of PY2Y2 nucleotide receptor mRNA in human uterine cervical cells,” American Journal of Physiology, vol. 275(3) Part.1:C758-C765 (1998).
Gorodeski, G.I., et al., “Retinoids modulate P2u purinergic receptor mediated changes in transcervical paracellular permeability,” IDS Foreign Search Report due May 16, 2001 taken off per VTK dtd Apr. 11, 2001 not related to the case, vol. 274(4):C1108-C1116 (1998).
Gorodeski, G.I., et al., “Nucleotide receptor-mediated decrease of tight-junctional permeability in cultured cervical epithelium,” American Journal of Physiology, vol. 270(6):C1715-1725 (1996).
Gorodeski, G.I., et al., “Regulation of the paracellular permeability of cultured human cervical epithelium by a nucleotide receptor,” Journal of Thesociey for Gynecologic Investigation, vol. 2(5) 76-720 (1995).
Drutz David J.
Pendergast William
Rideout Janet L.
Shaver Sammy Ray
Yerxa Benjamin R.
Crane L. E.
Howrey LLP
Inspire Pharmaceuticals Inc.
Jiang Shaojia Anna
Kung Viola T.
LandOfFree
Method of promoting cervical and vaginal secretions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of promoting cervical and vaginal secretions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of promoting cervical and vaginal secretions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015822